More research is needed to determine an optimal dose
As use of these drugs continues to expand, it becomes increasingly important to understand their real-world benefits and risks across populations. Guo conducted this research in collaboration with William Donahoo, M.D., clinical professor and chief of the UF Health Division of Endocrinology, Diabetes and Metabolism, and Steven T DeKosky, M.D., deputy director of the McKnight Brain Institute and professor of Alzheimer's research, neurology and neuroscience in the UF Department of Neurology
[DOI] [PubMed] [Google Scholar] Prvost M, Vertongen P, Raussens V, Roberts DJ, Cnuddle J, Perret J, et al
#GLP1 Reuters GLP-1 Insurance Coverage in Canada: Trends and Impact on Consumer Behaviour Another day, another story about GLP-1s